Operations at Natco Pharma Chennai factory temporarily disrupted due to cyclone
Hyderabad: Natco Pharma has announced that the operations at the Company's factory located at Manali Industrial Area, Chennai, Tamil Nadu have been temporarily disrupted due to cyclone with flooding/water logging of the factory premises.
"After following the required step process & safety measures, the factory operations have been shut down temporarily. Necessary steps are being taken to drain out the water. After careful evaluation and following all the regulatory procedures, the operations would be commenced at the earliest," Natco Pharma stated in a recent BSE filing.
The site manufactures Active Pharmaceucals Ingredient (API) Products for Cancer Medicines at the aforesaid factory.
"The Company will continue to service the customers uninterruptedly from the inventory of finished goods," Natco further stated.
Read also: Natco Pharma Pharmacovigilance department successfully completes USFDA inspection
"There is no material impact on the financial position or sales of the Company. The factory is adequately covered by insurance through the policy coverage," it added.
Medical Dialogues team had earlier reported that flash floods in the Teesta River had led to disruption in operations at Alembic Pharma's Sikkim-based manufacturing plant.
Read also: Flash floods in Teesta River: Alembic Pharma Sikkim plant manufacturing operations disrupted
Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (“FDF”) and active pharmaceutical ingredients (“APIs”). The company focuses primarily on niche therapeutic areas and complex products. It markets and distributes products in over 40 countries. It sells FDF products in the United States, India, Europe and the rest of the world (“RoW”). Natco also operates in certain key geographies through its subsidiaries.
Natco Pharma is also engaged in contract manufacturing business, whereby it undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.
Read also: Suresh Babu K resigns as Natco Pharma Vice President
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd